Verona Pharma plc Verona Pharma Plc : Miscellaneous

 
TIDMVRP 
 
 
   Issue of Shares 
 
   September 19, 2017, London - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) 
("Verona Pharma"), a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for respiratory 
diseases, announces that it will issue 133,333 new ordinary shares in 
the capital of the Company (the "New Shares") following an exercise of 
share options by N+1 Singer Capital Markets Limited. Application has 
been made to the London Stock Exchange for the New Shares to be admitted 
to trading on AIM, with dealings expected to commence on 22 September 
2017 ("Admission"). 
 
   Following Admission, the Company will have a total of 105,017,401 
Ordinary Shares in issue each carrying one voting right. The Company 
does not hold any Ordinary Shares in Treasury. This figure of 
105,017,401 Ordinary Shares may be used by shareholders as the 
denominator for the calculations by which they will determine if they 
are required to notify their interest in, or a change to their interest 
in, the share capital of the Company under the FCA's Disclosure and 
Transparency Rules. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapeutics for the treatment 
of respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function as compared to 
placebo and has shown clinically meaningful and statistically 
significant improvements in lung function when added to two commonly 
used bronchodilators as compared to either bronchodilator administered 
as a single agent. Verona Pharma is developing RPL554 for the treatment 
of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and 
potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker)                                     [e-mail] 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

September 19, 2017 07:46 ET (11:46 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.